The Petri Dish: Chaos at Sesen Bio, funding for rare disease drugs

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here’s The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.…

Read More

In a highly vaccinated field, life sciences leaders weigh mandates

Life sciences workers tend to trust the science developed by their own industry, so their vaccination rates are naturally high. But creating a mandate would send a message beyond a company’s labs: that vaccines are necessary for a shot at anything resembling a normal existence. Read More

Read More

Ginkgo Bioworks CEO touts lofty vision in first-ever earnings call

In the company’s first earnings call as a soon-to-be-publicly traded firm after its merger with a special-purpose acquisition company, Ginkgo Bioworks’ CEO and co-founder Jason Kelly didn’t spend most of his time focused on finances. Rather, he spent much of the call explaining to analysts the business model for the 12-year-old biotech company in terms…

Read More